CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: HYPERHIDROSIS TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Axillary hyperhidrosis
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Palmar hyperhidrosis
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Plantar hyperhidrosis
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Others
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Botulinum toxin injections
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Topical treatment
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Oral medication
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.4.4 Oral medication Hyperhidrosis Treatment Market by Type
5.4.4.1 Anticholinergics Market size and forecast, by region
5.4.4.2 Others Market size and forecast, by region
CHAPTER 6: HYPERHIDROSIS TREATMENT MARKET, BY AGE
6.1 Overview
6.1.1 Market size and forecast
6.2 Below 50 years
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Above 50 years
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: HYPERHIDROSIS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Treatment
7.2.3.1 North America Oral medication Hyperhidrosis Treatment Market by Type
7.2.4 North America Market size and forecast, by Age
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Treatment
7.2.5.1.3 Market size and forecast, by Age
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Treatment
7.2.5.2.3 Market size and forecast, by Age
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Treatment
7.2.5.3.3 Market size and forecast, by Age
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.3.1 Europe Oral medication Hyperhidrosis Treatment Market by Type
7.3.4 Europe Market size and forecast, by Age
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Treatment
7.3.5.1.3 Market size and forecast, by Age
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Treatment
7.3.5.2.3 Market size and forecast, by Age
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Treatment
7.3.5.3.3 Market size and forecast, by Age
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Treatment
7.3.5.4.3 Market size and forecast, by Age
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Treatment
7.3.5.5.3 Market size and forecast, by Age
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Treatment
7.3.5.6.3 Market size and forecast, by Age
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.3.1 Asia-Pacific Oral medication Hyperhidrosis Treatment Market by Type
7.4.4 Asia-Pacific Market size and forecast, by Age
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Treatment
7.4.5.1.3 Market size and forecast, by Age
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Treatment
7.4.5.2.3 Market size and forecast, by Age
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Treatment
7.4.5.3.3 Market size and forecast, by Age
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Treatment
7.4.5.4.3 Market size and forecast, by Age
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Treatment
7.4.5.5.3 Market size and forecast, by Age
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Treatment
7.4.5.6.3 Market size and forecast, by Age
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.3.1 LAMEA Oral medication Hyperhidrosis Treatment Market by Type
7.5.4 LAMEA Market size and forecast, by Age
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Treatment
7.5.5.1.3 Market size and forecast, by Age
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Treatment
7.5.5.2.3 Market size and forecast, by Age
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Treatment
7.5.5.3.3 Market size and forecast, by Age
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Treatment
7.5.5.4.3 Market size and forecast, by Age
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Avanor Healthcare Ltd
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Brickbell Biotech, Inc
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Dr August Wolff Gmbh & Co. Kg Drugs
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eirion Therapeutics, Inc
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Eli Lilly and Company
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Hugel, Inc
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Kaken Pharmaceutical Co., Ltd.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Roivant Sciences Ltd.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Theravida, Inc
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Dr. Reddy’s Laboratories Ltd.
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Intas Pharmaceuticals Ltd
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
TABLE 1. GLOBAL HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. HYPERHIDROSIS TREATMENT MARKET, FOR AXILLARY HYPERHIDROSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. HYPERHIDROSIS TREATMENT MARKET FOR AXILLARY HYPERHIDROSIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. HYPERHIDROSIS TREATMENT MARKET, FOR PALMAR HYPERHIDROSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. HYPERHIDROSIS TREATMENT MARKET FOR PALMAR HYPERHIDROSIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. HYPERHIDROSIS TREATMENT MARKET, FOR PLANTAR HYPERHIDROSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. HYPERHIDROSIS TREATMENT MARKET FOR PLANTAR HYPERHIDROSIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. HYPERHIDROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. HYPERHIDROSIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. GLOBAL HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 11. HYPERHIDROSIS TREATMENT MARKET, FOR BOTULINUM TOXIN INJECTIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. HYPERHIDROSIS TREATMENT MARKET FOR BOTULINUM TOXIN INJECTIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. HYPERHIDROSIS TREATMENT MARKET, FOR TOPICAL TREATMENT, BY REGION, 2021-2031 ($MILLION)
TABLE 14. HYPERHIDROSIS TREATMENT MARKET FOR TOPICAL TREATMENT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. HYPERHIDROSIS TREATMENT MARKET, FOR ORAL MEDICATION, BY REGION, 2021-2031 ($MILLION)
TABLE 16. HYPERHIDROSIS TREATMENT MARKET FOR ORAL MEDICATION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. GLOBAL ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 18. HYPERHIDROSIS TREATMENT MARKET, FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 19. HYPERHIDROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. GLOBAL HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 21. HYPERHIDROSIS TREATMENT MARKET, FOR BELOW 50 YEARS, BY REGION, 2021-2031 ($MILLION)
TABLE 22. HYPERHIDROSIS TREATMENT MARKET FOR BELOW 50 YEARS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. HYPERHIDROSIS TREATMENT MARKET, FOR ABOVE 50 YEARS, BY REGION, 2021-2031 ($MILLION)
TABLE 24. HYPERHIDROSIS TREATMENT MARKET FOR ABOVE 50 YEARS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. HYPERHIDROSIS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. U.S. HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 32. U.S. HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 33. U.S. HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 34. CANADA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 35. CANADA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 36. CANADA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 37. MEXICO HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 38. MEXICO HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 39. MEXICO HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 40. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 41. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 42. EUROPE ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 43. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 44. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 45. GERMANY HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 46. GERMANY HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 47. GERMANY HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 48. FRANCE HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 49. FRANCE HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 50. FRANCE HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 51. UK HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 52. UK HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 53. UK HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 54. ITALY HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 55. ITALY HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 56. ITALY HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 57. SPAIN HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 58. SPAIN HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 59. SPAIN HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 68. JAPAN HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 69. JAPAN HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 70. JAPAN HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 71. CHINA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 72. CHINA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 73. CHINA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 74. INDIA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 75. INDIA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 76. INDIA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 77. AUSTRALIA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 80. SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 86. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 87. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 88. LAMEA ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 89. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 90. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 91. BRAZIL HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 92. BRAZIL HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 93. BRAZIL HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 94. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 95. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 96. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 97. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 98. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 99. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 100. REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 101. REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 102. REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 103.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 104.ABBVIE INC.: OPERATING SEGMENTS
TABLE 105.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 106.ABBVIE INC.: NET SALES,
TABLE 107.ABBVIE INC.: KEY STRATERGIES
TABLE 108.AVANOR HEALTHCARE LTD: COMPANY SNAPSHOT
TABLE 109.AVANOR HEALTHCARE LTD: OPERATING SEGMENTS
TABLE 110.AVANOR HEALTHCARE LTD: PRODUCT PORTFOLIO
TABLE 111.AVANOR HEALTHCARE LTD: NET SALES,
TABLE 112.AVANOR HEALTHCARE LTD: KEY STRATERGIES
TABLE 113.BRICKBELL BIOTECH, INC: COMPANY SNAPSHOT
TABLE 114.BRICKBELL BIOTECH, INC: OPERATING SEGMENTS
TABLE 115.BRICKBELL BIOTECH, INC: PRODUCT PORTFOLIO
TABLE 116.BRICKBELL BIOTECH, INC: NET SALES,
TABLE 117.BRICKBELL BIOTECH, INC: KEY STRATERGIES
TABLE 118.DR AUGUST WOLFF GMBH & CO. KG DRUGS: COMPANY SNAPSHOT
TABLE 119.DR AUGUST WOLFF GMBH & CO. KG DRUGS: OPERATING SEGMENTS
TABLE 120.DR AUGUST WOLFF GMBH & CO. KG DRUGS: PRODUCT PORTFOLIO
TABLE 121.DR AUGUST WOLFF GMBH & CO. KG DRUGS: NET SALES,
TABLE 122.DR AUGUST WOLFF GMBH & CO. KG DRUGS: KEY STRATERGIES
TABLE 123.EIRION THERAPEUTICS, INC: COMPANY SNAPSHOT
TABLE 124.EIRION THERAPEUTICS, INC: OPERATING SEGMENTS
TABLE 125.EIRION THERAPEUTICS, INC: PRODUCT PORTFOLIO
TABLE 126.EIRION THERAPEUTICS, INC: NET SALES,
TABLE 127.EIRION THERAPEUTICS, INC: KEY STRATERGIES
TABLE 128.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 129.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 130.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 131.ELI LILLY AND COMPANY: NET SALES,
TABLE 132.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 133.HUGEL, INC: COMPANY SNAPSHOT
TABLE 134.HUGEL, INC: OPERATING SEGMENTS
TABLE 135.HUGEL, INC: PRODUCT PORTFOLIO
TABLE 136.HUGEL, INC: NET SALES,
TABLE 137.HUGEL, INC: KEY STRATERGIES
TABLE 138.KAKEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 139.KAKEN PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
TABLE 140.KAKEN PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 141.KAKEN PHARMACEUTICAL CO., LTD.: NET SALES,
TABLE 142.KAKEN PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
TABLE 143.ROIVANT SCIENCES LTD.: COMPANY SNAPSHOT
TABLE 144.ROIVANT SCIENCES LTD.: OPERATING SEGMENTS
TABLE 145.ROIVANT SCIENCES LTD.: PRODUCT PORTFOLIO
TABLE 146.ROIVANT SCIENCES LTD.: NET SALES,
TABLE 147.ROIVANT SCIENCES LTD.: KEY STRATERGIES
TABLE 148.THERAVIDA, INC: COMPANY SNAPSHOT
TABLE 149.THERAVIDA, INC: OPERATING SEGMENTS
TABLE 150.THERAVIDA, INC: PRODUCT PORTFOLIO
TABLE 151.THERAVIDA, INC: NET SALES,
TABLE 152.THERAVIDA, INC: KEY STRATERGIES
TABLE 153.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 154.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
TABLE 155.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 156.DR. REDDY'S LABORATORIES LTD.: NET SALES,
TABLE 157.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
TABLE 158.INTAS PHARMACEUTICALS LTD: COMPANY SNAPSHOT
TABLE 159.INTAS PHARMACEUTICALS LTD: OPERATING SEGMENTS
TABLE 160.INTAS PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
TABLE 161.INTAS PHARMACEUTICALS LTD: NET SALES,
TABLE 162.INTAS PHARMACEUTICALS LTD: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
